Nevro Corp.

NYSE:NVRO Stock Report

Market Cap: US$175.4m

Nevro Future Growth

Future criteria checks 0/6

Nevro is forecast to grow earnings and revenue by 5% and 3.2% per annum respectively. EPS is expected to grow by 6.9% per annum. Return on equity is forecast to be -35.3% in 3 years.

Key information

5.0%

Earnings growth rate

6.9%

EPS growth rate

Medical Equipment earnings growth16.6%
Revenue growth rate3.2%
Future return on equity-35.3%
Analyst coverage

Good

Last updated21 Jan 2025

Recent future growth updates

Recent updates

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Aug 11
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Nevro: Not Having My Back

Aug 09

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jul 16
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01
Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Feb 25
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Jan 08
There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nov 16
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Sep 01

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Jul 10
Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Feb 28
Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Feb 22

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Feb 14

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jan 13
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro: Opportunity Overshadowed By Weaknesses

Dec 07

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Oct 26

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Oct 13

Nevro gets FDA approval for Costa Rica manufacturing operations

Oct 04

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Oct 02
Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation

Sep 07

Earnings and Revenue Growth Forecasts

NYSE:NVRO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027450-70N/AN/A4
12/31/2026424-82-31-1613
12/31/2025408-93-33-1816
12/31/2024405-90-30-2014
9/30/2024419-69-57-47N/A
6/30/2024426-77-65-56N/A
3/31/2024431-83-71-62N/A
12/31/2023425-92-67-59N/A
9/30/2023423-102-72-63N/A
6/30/202341931322N/A
3/31/202341521524N/A
12/31/202240631725N/A
9/30/2022395-81623N/A
6/30/2022388-140-80-72N/A
3/31/2022386-136-75-63N/A
12/31/2021387-131-54-42N/A
9/30/2021394-108-28-15N/A
6/30/2021409-68112N/A
3/31/2021363-88-80N/A
12/31/2020362-83-51N/A
9/30/2020367-90-29-24N/A
6/30/2020358-98-43-39N/A
3/31/2020396-84-37-34N/A
12/31/2019390-104-54-50N/A
9/30/2019384-100-34-32N/A
6/30/2019379-93-37-34N/A
3/31/2019382-76-25-21N/A
12/31/2018387-49-14-6N/A
9/30/2018377-44-23-13N/A
6/30/2018364-39N/A-2N/A
3/31/2018346-40N/A-7N/A
12/31/2017327-37N/A-14N/A
9/30/2017299-42N/A-27N/A
6/30/2017278-40N/A-35N/A
3/31/2017255-37N/A-42N/A
12/31/2016229-32N/A-59N/A
9/30/2016191-36N/A-73N/A
6/30/2016146-52N/A-101N/A
3/31/2016102-63N/A-114N/A
12/31/201570-67N/A-100N/A
9/30/201546-62N/A-79N/A
6/30/201539-50N/A-57N/A
3/31/201536-38N/A-40N/A
12/31/201433-31N/A-31N/A
9/30/201429-29N/A-27N/A
6/30/201427-26N/A-24N/A
3/31/201425-26N/A-22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NVRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NVRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NVRO's revenue (3.2% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: NVRO's revenue (3.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NVRO is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 07:07
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nevro Corp. is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
null nullBaird
Michael PolarkBaird